Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

335
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
335
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

371
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
371
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

363
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
363

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Clinical pharmacology and therapeutics·2026
Same author

Lineage-encoded genomic determinants of neonatal invasive Group B Streptococcal disease.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
Same author

Antibiotic overuse in children with viral infections: lessons from the SARS-CoV-2 pandemic.

BMJ paediatrics open·2026
Same author

Identification, reliability, and validity of drug-drug interaction checkers in chronic diseases: A systematic review.

British journal of pharmacology·2026
Same author

Genome-wide association study of paediatric bacteraemia and sepsis.

EBioMedicine·2026
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
Same journal

ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma.

Clinical pharmacokinetics·2026
Same journal

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Clinical pharmacokinetics·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

33.2K

Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study.

Anne Ravix1, Yann Thoma2, Annie Cathignol2

  • 1Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011, Lausanne, Switzerland.

Clinical Pharmacokinetics
|May 2, 2026
PubMed
Summary
This summary is machine-generated.

Bayesian model-informed precision dosing (MIPD) effectively optimizes vancomycin (ideal for therapeutic drug monitoring [TDM]) in neonates, simplifying sampling strategies for improved drug exposure and patient outcomes.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

5.5K
Establishing the Minimal Bactericidal Concentration of an Antimicrobial Agent for Planktonic Cells MBC-P and Biofilm Cells MBC-B
06:36

Establishing the Minimal Bactericidal Concentration of an Antimicrobial Agent for Planktonic Cells MBC-P and Biofilm Cells MBC-B

Published on: January 2, 2014

19.4K

Related Experiment Videos

Last Updated: May 4, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
11:28

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically

Published on: September 9, 2015

33.2K
A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

5.5K
Establishing the Minimal Bactericidal Concentration of an Antimicrobial Agent for Planktonic Cells MBC-P and Biofilm Cells MBC-B
06:36

Establishing the Minimal Bactericidal Concentration of an Antimicrobial Agent for Planktonic Cells MBC-P and Biofilm Cells MBC-B

Published on: January 2, 2014

19.4K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Neonatal Pharmacology
  • Computational Modeling in Medicine

Background:

  • Therapeutic drug monitoring (TDM) of vancomycin in neonates is challenging due to sampling limitations.
  • Trough concentration (Ctrough) is often used as a surrogate for the ideal AUC24,SS/MIC ratio.
  • This limits precise vancomycin dosing and optimal therapeutic exposure in this vulnerable population.

Purpose of the Study:

  • To evaluate the performance of Bayesian model-informed precision dosing (MIPD) for vancomycin in neonates.
  • To compare MIPD strategies against traditional TDM approaches using simulated data.
  • To assess the feasibility of simplified sampling for vancomycin TDM in neonatal intensive care.

Main Methods:

  • A virtual TDM study simulating 1000 neonates using a population pharmacokinetic (PK) model.
  • Comparison of four TDM strategies: no adjustment, standard Ctrough targeting, and two Bayesian MIPD approaches (Tucuxi software).
  • Evaluation of target attainment (AUC24,SS/MIC between 360-540 h) and optimal sampling times.

Main Results:

  • Standard TDM strategies achieved suboptimal target attainment (<49% without adjustment, 75% with Ctrough targeting at specific intervals).
  • Bayesian MIPD strategies (Tucuxi) allowed >74% target attainment after one cycle and 100% after four cycles.
  • A single blood sample was sufficient for accurate vancomycin AUC24,SS prediction using MIPD.

Conclusions:

  • Bayesian MIPD significantly optimizes vancomycin exposure in neonates compared to traditional methods.
  • MIPD simplifies TDM by reducing the required number of samples for accurate dosing.
  • This approach warrants integration and validation in routine neonatal clinical practice.